Clement Tsui PhD 🇭🇰 🇨🇦

@clementsui.bsky.social

- Prin Scientific Officer, NCID, Singapore - Asst Prof @UBC Canada - Asst Prof @NTU Singapore - views are my own - Editor, tea lover, hiker #microbiology #mycology #evolutionarybiology #genomics #AMR

Deciphering the multidrug resistance paradigm in Candida auris | Antimicrobial Agents and Chemotherapy journals.asm.org/doi/10.1128/...

Deciphering the multidrug resistance paradigm in Candida auris | Antimicrobial Agents and Chemotherapy

Candida auris (taxonomically reclassified as Candidozyma auris [1]) is often described as a paragon of antifungal resistance among fungal species. Like the related Candida haemulonii (reclassified as Candidozyma haemuli) complex members, C. auris demonstrates a notably high propensity for antifungal resistance compared to more commonly clinically isolated but genetically distant Candida species. As C. auris has emerged and become more commonly established, concerns around diminishing therapeutic options in an already limited arsenal of antifungal drugs have prompted substantial warnings from clinical and public health authorities (2–4). Our understanding of C. auris antifungal resistance is grounded in early studies that characterized the global spread of this pathogen (5, 6). While the numbers vary across regional reports, nearly 90% of clinical isolates are resistant to at least fluconazole, a widely administered triazole-class drug, while up to 30% of isolates are reportedly also resistant to a drug in at least one other antifungal class. Research in subsequent years has deeply investigated mechanisms and patterns in C. auris antifungal resistance, presenting the opportunity for reexamination to identify therapeutically useful insights (7–9).

journals.asm.org